arGEN-X huge outperformer in European biotech sector

Thanks to the huge profit of 32 percent since begin this year it's one of the best shares of the biotech sector.

Momentum biotech sector

On average the sector trades costs now 52 times the earnings per share. The sector trades now at -12,98 times the book value per share. Since 2012 the sector has a profit of 193 percent and since 2007 a profit of 268 percent.

Over the current book year the total revenue will be 72,79 million euros (consensus estimates). This is slightly more than 2018's revenue of 69,78 million euros.

Historical revenues and results arGEN-X plus estimates 2020

The analysts expect for 2020 a net loss of 221 million euros. Most of the analysts anticipate on a loss per share of 5,39 euros. Based on this the price/earnings-ratio is -35,25.

For this year analysts don't expect the company to pay a dividend. The average dividend yield of the biotech companies is a limited 1,16 percent.

Most recent target prices around 173 euros

The most recent recommendations for the biotech company are from DeGroof Petercam, KBC Securities and Kepler Capital Markets.

Based on the current number of outstanding shares arGEN-X's market capitalization 6,84 billion euros. The arGEN-X stock was the past 12 months quite unstable. Since last May the stock is even 64 percent higher. This year the stock price moved between 93 and 195 euro.

Historical stock prices arGEN-X past 10 years

Click here for dividend arGEN-X. At 13.00 the stock trades 4,21 percent higher at 190 euros.

Analist.nl Nieuwsdienst: +31 084-0032-842
nieuws@analist.nl

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.